Abstract
Objective:To observe the clinical efficacy of pidotimod in the treatment of recurrent respiratory tract infection in children.Methods:One hundred thirty-two patients with recurrent respiratory tract infection who received treatment in Tianan City Central Hospital were selected and divided into an observation group and a control group using random number table, 66 in each group. Patients in the control group were given conventional treatment, while patients in the observation group were given conventional treatment and pidotimod treatment; the clinical efficacy of the two therapies was compared. The levels of IgG and IgM were measured after treatment.Results:The vital signs and the content of inflammatory mediator and Th1/Th2 in serum before and after treatment were compared, and the clinical efficacy of the two groups was evaluated. The fever, pulmonary rale, cough and antiadoncus of patients in the observation group disappeared earlier than those in the control group (P<0.05). The onset duration of respiratory tract infection and days of antibiotic application of the observation group were shorter than those of the control group after treatment (P<0.05). The times of infection of the observation group were less than that of the control group (P<0.05). Before treatment, the two groups had no significant difference in the content of inflammatory mediators and Th1/Th2 in the serum (P>0.05). The serum content of tumor necrosis factor (TNF)-α and interleukin (IL)-4 of the two groups one week after treatment was lower than that before treatment, and the content of interferon (IFN)-γ and IFN-γ/IL-4 were higher than that before treatment; moreover the observation group had lower serum content of TFN-α and IL-4 and lower content of IFN-γ and IFN-γ/IL-4 compared to the control group (P<0.05). The overall response rate of the observation group was 92.4%, much higher than 81.8% in the control group (P<0.05).Conclusion:Pidotimod has a remarkable efficacy in the treatment of pediatric recurrent respiratory tract infection because it can effectively inhibit the infection and optimize Th1/Th2 immune function.
Highlights
Pediatric recurrent respiratory infection is a respiratory infection disease with frequent episode in the upper and lower respiratory tracts of children
This study aims to discuss the influence of pidotimod on the infection status and immune function of children with recurrent respiratory infection and provide a basis for the treatment of pediatric recurrent respiratory infection
A previous study found that the immune function of children with recurrent respiratory tract infection was generally weaker than that of normal children and considered that abnormal immune function was an important cause of recurrent respiratory
Summary
Pediatric recurrent respiratory infection is a respiratory infection disease with frequent episode in the upper and lower respiratory tracts of children. It is common in clinical pediatrics, and its incidence is about 20%.1-3. The pathogenesis of pediatric recurrent respiratory infection is not clear. It may be related to the congenital factors, decline of immunity, deficiency of trace elements, Pak J Med Sci July - August 2019 Vol 35 No 4 www.pjms.org.pk 981 the improper feeding and living environment.[4,5] Children with recurrent respiratory infection have symptoms of night sweat, dyspnea and nasal obstruction. Delayed treatment or therapeutic error can cause a series of complications such as myocarditis, which may seriously affect the quality of life and even inhibit the normal growth and development of children
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
